Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kim, Hyo Young ^a   Yum, Soo Young ^c   Jang, Goo ^c,d   Ahn, Dae Ro ^a,b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; BETA GALACTOSIDASE; CATION; CELL PENETRATING PEPTIDE; DRUG CARRIER; ISOPROTEIN; MEMBRANE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; CELL FRACTIONATION; CELL MEMBRANE; CHEMISTRY; CIRCULAR DICHROISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; ENDOCYTOSIS; HELA CELL LINE; HUMAN; INTRACELLULAR SPACE; METABOLISM; MOLECULAR GENETICS; MOUSE; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN TRANSPORT; RAW 264.7 CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANNEXINS; BETA-GALACTOSIDASE; CATIONS; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; CIRCULAR DICHROISM; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENDOCYTOSIS; HELA CELLS; HUMANS; INTRACELLULAR SPACE; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN ISOFORMS; PROTEIN STABILITY; PROTEIN TRANSPORT; RAW 264.7 CELLS; SUBCELLULAR FRACTIONS;

EID: 84933567840     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11719     Document Type: Article

References (49)

1. Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189-1193 (1988).
2. Nakase, I. et al. Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis. Mol Ther 17, 1868-1876, doi: 10.1038/mt.2009.192 (2009).
3. Balayssac, S. et al. Comparison of penetratin and other homeodomain-derived cell-penetrating peptides: interaction in a membrane-mimicking environment and cellular uptake efficiency. Biochemistry 45, 1408-1420, doi: 10.1021/bi0518390 (2006).
4. De Coupade, C. et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J 390, 407-418, doi: 10.1042/BJ20050401 (2005).
5. Magzoub, M. et al. N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys Res Commun 348, 379-385, doi: 10.1016/j.bbrc.2006.07.065 (2006).
6. Chaloin, L. et al. Conformations of primary amphipathic carrier peptides in membrane mimicking environments. Biochemistry 36, 11179-11187, doi: 10.1021/bi9708491 (1997).
7. Duchardt, F. et al. A cell-penetrating peptide derived from human lactoferrin with conformation-dependent uptake efficiency. J Biol Chem 284, 36099-36108, doi: 10.1074/jbc.M109.036426 (2009).
8. Sadler, K., Eom, K. D., Yang, J. L., Dimitrova, Y. & Tam, J. P. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 41, 14150-7, doi: 10.1021/bi026661I (2002).
9. Godet, A. N. et al. PP2A1 binding, cell transducing and apoptotic properties of Vpr(77-92): a new functional domain of HIV-1 Vpr proteins. PLoS One 5, e13760, doi: 10.1371/journal.pone.0013760 (2010).
10. Lu, S., Tager, L. A., Chitale, S. & Riley, L. W. A cell-penetrating peptide derived from mammalian cell uptake protein of Mycobacterium tuberculosis. Anal Biochem 353, 7-14, doi: 10.1016/j.ab.2006.01.044 (2006).
11. Hawiger, J. Noninvasive intracellular delivery of functional peptides and proteins. Curr Opin Chem Biol 3, 89-94, doi: 10.1016/ S1367-5931(99)80016-7 (1999).
12. Wang, F. et al. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control Release 174, 126-136, doi: 10.1016/j.jconrel.2013.11.020 (2014).
13. Vives, E., Schmidt, J. & Pelegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786, 126-138, doi: 10.1016/j.bbcan.2008.03.001 (2008).
14. Goni, F. M. Non-permanent proteins in membranes: when proteins come as visitors (Review). Mol Membr Biol 19, 237-45, doi: 10.1080/0968768021000035078 (2002).
15. Cho, W. & Stahelin, R. V. Membrane-protein interactions in cell signaling and membrane trafficking. Annu Rev Biophys Biomol Struct 34, 119-51, doi: 10.1146/annurev.biophys.33.110502.133337 (2005).
16. Lizarbe, M. A., Barrasa, J. I., Olmo, N., Gavilanes, F. & Turnay, J. Annexin-phospholipid interactions. Functional implications. Int J Mol Sci 14, 2652-83, doi: 10.3390/ijms14022652 (2013).
17. Jacobs, M., Freedman, S. J., Furie, B. C. & Furie, B. Membrane binding properties of the factor IX gamma-carboxyglutamic acidrich domain prepared by chemical synthesis. J Biol Chem 269, 25494-501 (1994).
18. Gerke, V., Creutz, C. E. & Moss, S. E. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6, 449-61, doi: 10.1038/nrm1661 (2005).
19. Gerke, V. & Moss, S. E. Annexins: from structure to function. Physiol Rev 82, 331-71, doi: 10.1152/physrev.00030.2001 (2002).
20. Scharf, B. et al. Annexin A2 binds to endosomes following organelle destabilization by particulate wear debris. Nat Commun 3, 755, doi: 10.1038/ncomms1754 (2012).
21. Gerke, V. & Moss, S. E. Annexins and membrane dynamics. Biochim Biophys Acta 1357, 129-54 (1997).
22. Dutta, D. & Donaldson, J. G. Search for inhibitors of endocytosis: Intended specificity and unintended consequences. Cell Logist 2, 203-208, doi: 10.4161/cl.23967 (2012).
23. Kumari, S., Mg, S. & Mayor, S. Endocytosis unplugged: multiple ways to enter the cell. Cell Res 20, 256-75, doi: 10.1038/ cr.2010.19 (2010).
24. Poon, G. M. & Gariepy, J. Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem Soc Trans 35, 788-93, doi: 10.1042/BST0350788 (2007).
25. Bechara, C. et al. Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis. FASEB J 27, 738-49, doi: 10.1096/fj.12-216176 (2013).
26. Bandorowicz, J. & Pikula, S. Annexins - multifunctional, calcium-dependent, phospholipid-binding proteins. Acta Biochim Pol 40, 281-93 (1993).
27. Zaro, J. L. & Shen, W. C. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem Biophys Res Commun 307, 241-7 (2003).
28. Richard, J. P. et al. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280, 15300-6, doi: 10.1074/jbc.M401604200 (2005).
29. Patel, L. N., Zaro, J. L. & Shen, W. C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 24, 1977-92, doi: 10.1007/s11095-007-9303-7 (2007).
30. LeDoan, T., Etore, F., Tenu, J. P., Letourneux, Y. & Agrawal, S. Cell binding, uptake and cytosolic partition of HIV anti-gag phosphodiester oligonucleotides 3'-linked to cholesterol derivatives in macrophages. Bioorg Med Chem 7, 2263-9 (1999).
31. Eggimann, G. A., Buschor, S., Darbre, T. & Reymond, J. L. Convergent synthesis and cellular uptake of multivalent cell penetrating peptides derived from Tat, Antp, pVEC, TP10 and SAP. Org Biomol Chem 11, 6717-33, doi: 10.1039/c3ob41023d (2013).
32. Eiriksdottir, E., Konate, K., Langel, U., Divita, G. & Deshayes, S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta 1798, 1119-28, doi: 10.1016/j.bbamem.2010.03.005 (2010).
33. Sarko, D. et al. The pharmacokinetics of cell-penetrating peptides. Mol Pharm 7, 2224-31, doi: 10.1021/mp100223d (2010).
34. Soromou, L. W. et al. Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-O-methyl-naringenin. Molecules 17, 3574-85, doi: 10.3390/molecules17033574 (2012).
35. Lin, C. W. & Ting, A. Y. Transglutaminase-catalyzed site-specific conjugation of small-molecule probes to proteins in vitro and on the surface of living cells. J Am Chem Soc 128, 4542-3, doi: 10.1021/ja0604111 (2006).
36. Moon, J. et al. Production of porcine cloned embryos derived from cells conditionally expressing an exogenous gene using CreloxP. Zygote 20, 423-5, doi: 10.1017/S0967199411000773 (2012).
37. Zorko, M. & Langel, U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 57, 529-45, doi: 10.1016/j.addr.2004.10.010 (2005).
38. Shi, N. Q., Qi, X. R., Xiang, B. & Zhang, Y. A survey on "Trojan Horse" peptides: Opportunities, issues and controlled entry to "Troy". J Control Release 194C, 53-70, doi: 10.1016/j.jconrel.2014.08.014 (2014).
39. Wang, H. et al. Cell-Penetrating Apoptotic Peptide/p53 DNA Nanocomplex as Adjuvant Therapy for Drug-Resistant Breast Cancer. Mol Pharm, doi: 10.1021/mp5001058 (2014).
40. Nielsen, E. J. et al. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J Control Release 189, 19-24, doi: 10.1016/j.jconrel.2014.06.022 (2014).
41. Chen, Z. et al. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. J Control Release 191, 123-30, doi: 10.1016/j.jconrel.2014.05.051 (2014).
42. Sayers, E. J., Cleal, K., Eissa, N. G., Watson, P. & Jones, A. T. Distal phenylalanine modification for enhancing cellular delivery of fluorophores, proteins and quantum dots by cell penetrating peptides. J Control Release, doi: 10.1016/j.jconrel.2014.07.055 (2014).
43. Peng, L. H. et al. TAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells. Biomaterials 35, 5605-18, doi: 10.1016/j.biomaterials.2014.03.062 (2014).
44. Biswas, S. et al. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett 335, 191-200, doi: 10.1016/j.canlet.2013.02.020 (2013).
45. Khafagy el, S. & Morishita, M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 64, 531-9, doi: 10.1016/j. addr.2011.12.014 (2012).
46. Knappe, D., Henklein, P., Hoffmann, R. & Hilpert, K. Easy strategy to protect antimicrobial peptides from fast degradation in serum. Antimicrob Agents Chemother 54, 4003-5, doi: 10.1128/AAC.00300-10 (2010).
47. Verdurmen, W. P. & Brock, R. Biological responses towards cationic peptides and drug carriers. Trends Pharmacol Sci 32, 116-24, doi: 10.1016/j.tips.2010.11.005 (2011).
48. Holm, T. et al. Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. Biochim Biophys Acta 1808, 1544-51, doi: 10.1016/j.bbamem.2010.10.019 (2011).
49. Futter, C. E., Felder, S., Schlessinger, J., Ullrich, A. & Hopkins, C. R. Annexin I is phosphorylated in the multivesicular body during the processing of the epidermal growth factor receptor. J Cell Biol 120, 77-83 (1993).